Last reviewed · How we verify
Femanest plus Gestapuran
Femanest plus Gestapuran is a hormonal combination therapy designed to support pregnancy maintenance and reduce miscarriage risk through progestin supplementation.
Femanest plus Gestapuran is a hormonal combination therapy designed to support pregnancy maintenance and reduce miscarriage risk through progestin supplementation. Used for Recurrent miscarriage prevention in early pregnancy, Luteal phase support in assisted reproductive technology.
At a glance
| Generic name | Femanest plus Gestapuran |
|---|---|
| Sponsor | Karolinska University Hospital |
| Drug class | Hormonal combination therapy / Progestin + Estrogen |
| Modality | Small molecule |
| Therapeutic area | Obstetrics / Reproductive Medicine |
| Phase | Phase 3 |
Mechanism of action
The drug combines estrogen and progestin components to provide hormonal support during early pregnancy. Gestapuran (a progestin) helps maintain the endometrium and supports corpus luteum function, while the estrogen component may enhance uterine receptivity and placental development. This combination is intended to reduce the risk of recurrent miscarriage in women with hormonal insufficiency.
Approved indications
- Recurrent miscarriage prevention in early pregnancy
- Luteal phase support in assisted reproductive technology
Common side effects
- Nausea
- Breast tenderness
- Headache
- Vaginal bleeding or spotting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Femanest plus Gestapuran CI brief — competitive landscape report
- Femanest plus Gestapuran updates RSS · CI watch RSS
- Karolinska University Hospital portfolio CI